Connect your AI

CorMedix CRMD Restricted cash equivalents included in Other long-term assets

Restricted cash equivalents included in Other long-term assets at other companies

TFX

TeleflexTFX

——

Other financials

Income statement

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashEquivalentsNoncurrent.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's restricted cash equivalents included in other long-term assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CorMedix's restricted cash equivalents included in other long-term assets?: CorMedix (CRMD) reported restricted cash equivalents included in other long-term assets of $332K in Q1 2026.